At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CELZ Creative Medical Technology Holdings, Inc.
Post-Mkt 10-05 19:43:59 EDT
0.9200
-0.0264
-2.79%
盘后0.9150
-0.0050-0.54%
19:43 EDT
High0.9600Low0.9200Vol75.29K
Open0.9600D1 Closing0.9464Amplitude4.23%
Mkt Cap6.99MTradable Cap6.95MTotal Shares7.59M
T/O70.04KT/O Rate1.00%Tradable Shares7.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Creative Medical Technology - Holds 80% of Biodefense After Deal - SEC Filing
THOMSON REUTERS  ·  09-26
Creative Medical Technology - Holds 80% of Biodefense After Deal - SEC Filing
Creative Medical Technology - Buys 4 Mln Biodefense Shares for $200,000 Cash and 1 Mln Shares on Sept 24 - SEC Filing
THOMSON REUTERS  ·  09-26
Creative Medical Technology - Buys 4 Mln Biodefense Shares for $200,000 Cash and 1 Mln Shares on Sept 24 - SEC Filing
Creative Medical Files New US Provisional Patent to Expand Ultrasome Cell-Free Platform Protection
Reuters  ·  09-17
Creative Medical Files New US Provisional Patent to Expand Ultrasome Cell-Free Platform Protection
Creative Medical Technology - Files New U.S. Provisional Patent Application
THOMSON REUTERS  ·  09-17
Creative Medical Technology - Files New U.S. Provisional Patent Application
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
GlobeNewswire  ·  09-17
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Creative Medical Technology Holdings Stockholders Approved Increase in Authorized Common Shares to 100 Million
Reuters  ·  09-01
Creative Medical Technology Holdings Stockholders Approved Increase in Authorized Common Shares to 100 Million
Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’
TIPRANKS  ·  08-21
Roth believes Creative Medical’s ADAPT trial in CLBO ‘likely to succeed’
Creative Medical Completes Enrollment, Treatment in FDA-Cleared ADAPT Trial of Olastrocel for Chronic Lower Back Pain
Reuters  ·  08-20
Creative Medical Completes Enrollment, Treatment in FDA-Cleared ADAPT Trial of Olastrocel for Chronic Lower Back Pain
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation and Phase 3 Planning
THOMSON REUTERS  ·  08-20
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation and Phase 3 Planning
Creative Medical Technology Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-08
Creative Medical Technology Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Creative Medical Net Loss Widens 22.5% to $1.51 Million in Q2 2026
Reuters  ·  08-08
Creative Medical Net Loss Widens 22.5% to $1.51 Million in Q2 2026
NASDAQ Trade Halt Volatility Trading Pause at 10:50 Am
Reuters  ·  08-06
NASDAQ Trade Halt Volatility Trading Pause at 10:50 Am
Creative Medical receives notice of allowance for new U.S. patent
TIPRANKS  ·  08-06
Creative Medical receives notice of allowance for new U.S. patent
Creative Medical Technology - Patent to Extend Ip Protection for Myelocelz Platform in Type 1 Diabetes
THOMSON REUTERS  ·  08-06
Creative Medical Technology - Patent to Extend Ip Protection for Myelocelz Platform in Type 1 Diabetes
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
GlobeNewswire  ·  08-06
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Top Premarket Gainers
MT Newswires Live  ·  08-06
Top Premarket Gainers
Creative Medical Technology Holdings Inc Expected to Post a Loss of 39 Cents a Share - Earnings Preview
Reuters  ·  08-05
Creative Medical Technology Holdings Inc Expected to Post a Loss of 39 Cents a Share - Earnings Preview
Creative Medical Technology Holdings Issues Mid-year Update
THOMSON REUTERS  ·  07-01
Creative Medical Technology Holdings Issues Mid-year Update
Creative Medical Technology Holdings Issues Mid-Year Update
GlobeNewswire  ·  07-01
Creative Medical Technology Holdings Issues Mid-Year Update
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds
THOMSON REUTERS  ·  07-01
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Introduction

Company Name.
Creative Medical Technology Holdings, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Issue price:
--